As filed with the Securities and Exchange Commission on March 24, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES
ACT OF 1933
Bionano
Genomics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
26-1756290
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
|
9540 Towne Centre Drive, Suite 100
San Diego, California
|
92121
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan
(Full titles of the plans)
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
Thomas A. Coll, Esq.
James C. Pennington, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000
|
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
|
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated
filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
Emerging growth company
|
☒
|
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
Title of Securities
to be Registered
|
Amount
to be
Registered(1)
|
Proposed
Maximum
Offering Price
Per Share(2)
|
Proposed
Maximum
Aggregate
Offering Price(2)
|
Amount of
Registration Fee
|
|||
|
2018 Equity Incentive Plan, as amended
Common Stock, $0.0001 par value per share
|
9,497,647(3)
|
$8.90
|
$84,529,058.30
|
$9,222.13
|
|||
|
2018 Employee Stock Purchase Plan
Common Stock, $0.0001 par value per share
|
220,000(4)
|
$8.90
|
$1,958,000
|
$213.62
|
|||
|
Total
|
9,717,647
|
$86,487,058.30
|
$9,435.75
|
||||
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Common Stock (“Common Stock”) of Bionano Genomics, Inc. (the “Registrant”) that become issuable under the Registrant’s 2018 Equity Incentive
Plan, as amended (the “2018 Plan”) or the Registrant’s 2018 Employee Stock Purchase Plan (the “2018 ESPP”) by reason of
any stock dividend, stock split, recapitalization or other similar transaction.
|
||||||
|
(2)
|
This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are
based upon the average of the high and low sale prices of the Common Stock on March 18, 2021, as reported on the Nasdaq Capital Market.
|
||||||
|
(3)
|
Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2021 pursuant to an “evergreen” provision contained in the 2018 Plan. Pursuant to such provision, on
January 1st of each year through January 1, 2028, the number of shares authorized for issuance under the 2018 Plan will be automatically increased by the lesser
of: (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31 of the preceding calendar year; or (b) such lesser number of shares of Common Stock as the Registrant’s board of directors (the “Board”) may designate prior to the applicable January 1st.
|
||||||
|
(4)
|
Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 ESPP on January 1, 2021 pursuant to an “evergreen” provision contained in the 2018 ESPP. Pursuant to such provision, on
January 1st of each year through January 1, 2028, the number of shares authorized for issuance under the 2018 ESPP will be automatically increased by a number
equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 220,000 shares; or (c) such lesser number of shares of Common Stock as the Board may designate prior
to the applicable January 1st.
|
||||||
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is
effective.
The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on August 28, 2018 (File No. 333-227073), March 29, 2019 (File No. 333-230589), March 11, 2020
(File No. 333-237069) and August 14, 2020 (File No. 333-245764). Pursuant to General Instruction E to Form S-8, this Registration Statement
hereby incorporates by reference the contents of the Registration Statements referenced above.
ITEM 8. EXHIBITS.
|
Exhibit
Number
|
Description
|
|
|
Amended and Restated Certificate of Incorporation of the Registrant, as amended.
|
||
|
Amended and Restated Bylaws of the Registrant.
|
||
|
Form of Common Stock Certificate of the Registrant.
|
||
|
Opinion of Cooley LLP.
|
||
|
Consent of BDO USA LLP, Independent Registered Public Accounting Firm.
|
||
|
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
|
||
|
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
|
||
|
Power of Attorney. Reference is made to the signature page hereto.
|
||
|
Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended.
|
||
|
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Plan.
|
||
|
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.
|
|
(1)
|
Incorporated by reference to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 23, 2021.
|
|
(2)
|
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 24, 2018.
|
|
(3)
|
Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-225970), as amended.
|
|
(4)
|
Incorporated by reference to the Registrant’s Registration Statement on Form S-8 (File No. 333-245764).
|
|
(5)
|
Incorporated by reference to the Registrant’s Registration Statement on Form S-8 (File No. 333-227073).
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 24, 2021.
|
BIONANO GENOMICS, INC.
|
||
|
By:
|
/s/ R. Erik Holmlin, Ph.D.
|
|
|
R. Erik Holmlin, Ph.D.
|
||
|
President and Chief Executive Officer
|
||
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or
her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
Signature
|
Title
|
Date
|
||
|
/s/ R. Erik Holmlin,Ph.D.
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
March 24, 2021
|
||
|
R. Erik Holmlin, Ph.D.
|
||||
|
/s/ Christopher Stewart
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
March 24, 2021
|
||
|
Christopher Stewart
|
||||
|
/s/ David L. Barker, Ph.D.
|
Director
|
March 24, 2021
|
||
|
David L. Barker, Ph.D.
|
||||
|
/s/ Yvonne Linney, Ph.D.
|
Director
|
March 24, 2021
|
||
|
Yvonne Linney, Ph.D.
|
||||
|
/s/ Albert A. Luderer, Ph.D.
|
Director
|
March 24, 2021
|
||
|
Albert A. Luderer, Ph.D.
|
||||
|
/s/ Hannah Mamuszka
|
Director
|
March 24, 2021
|
||
|
Hannah Mamuszka
|
||||
|
/s/ Christopher Twomey
|
Director
|
March 24, 2021
|
||
|
Christopher Twomey
|
||||
|
/s/ Kristiina Vuori, M.D., Ph.D.
|
Director
|
March 24, 2021
|
||
|
Kristiina Vuori, M.D., Ph.D.
|
Thomas A. Coll
+1 858 550 6013
collta@cooley.com
March 24, 2021
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, CA 92121
Ladies and Gentlemen:
You have requested our opinion, as counsel to Bionano Genomics, Inc., a Delaware corporation (the “Company”), in connection with the filing by the Company of
a Registration Statement on Form S‑8 (the “Registration Statement”) with the Securities and Exchange Commission covering the offering of an aggregate of up to 9,717,647 shares (the “Shares”) of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”), including (i) 9,497,647 shares of Common Stock
issuable pursuant to the Company’s 2018 Equity Incentive Plan (the “Incentive Plan”) and (ii) 220,000 shares of Common Stock issuable pursuant to the Company’s 2018 Employee Stock Purchase
Plan (together with the Incentive Plan, the “Plans”).
In connection with this opinion, we have examined and relied upon the Registration Statement and related prospectuses, the Plans, the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated
Bylaws, each as currently in effect, and originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion
expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of
certificates of public officials; and the due authorization, execution and delivery of all documents other than by the Company where authorization, execution and delivery are prerequisites to the effectiveness of such documents. As to certain
factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no
opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectus, will be validly
issued, fully paid and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).
Cooley LLP 4401 Eastgate Mall San Diego, CA 92121
t: (858) 550-6000 f: (858) 550-6420 cooley.com
t: (858) 550-6000 f: (858) 550-6420 cooley.com
March 24, 2021
Page Two
We consent to the filing of this opinion as an exhibit to the Registration Statement.
Sincerely,
Cooley LLP
| By: |
/s/ Thomas A. Coll
|
|
|
Thomas A. Coll
|
|
Cooley LLP 4401 Eastgate Mall San Diego, CA 92121
t: (858) 550-6000 f: (858) 550-6420 cooley.com
t: (858) 550-6000 f: (858) 550-6420 cooley.com
Consent of Independent Registered Public Accounting Firm
Bionano Genomics, Inc.
San Diego, California
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 23, 2021, relating to the consolidated financial statements of Bionano Genomics, Inc., appearing in the Company’s Annual
Report on Form 10-K of Bionano Genomics, Inc. for the year ended December 31, 2020.
/s/ BDO USA, LLP
San Diego, California
March 24, 2021
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 10, 2020 relating to the financial statements of Bionano Genomics, Inc. for the year ended December 31, 2019, appearing in the Annual
Report on Form 10-K of Bionano Genomics, Inc. for the year ended December 31, 2020.
/s/ DELOITTE & TOUCHE LLP
San Diego, CA
March 24, 2021